Cetera Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Cetera Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-222	Closed	-$3K	–	1500
2022 Q1	$3K	Hold	222	–	–	﹤0.01%	1404
2021 Q4	$2K	Sell	222 -222	-50%	-$3.99K	﹤0.01%	1432
2021 Q3	$14K	Buy	444 +222	+100%	+$7.2K	﹤0.01%	1399
2021 Q2	$10K	Hold	222	–	–	﹤0.01%	1312
2021 Q1	$11K	Buy	+222	New	+$12.2K	﹤0.01%	1208

Other funds holding FRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cetera Advisors's FRTX Position: Q2 2022 in Review

Cetera Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2022, closing a stake of 222 shares — an estimated $3K sold.

Cetera Advisors first reported a position in FRTX in Q1 2021 and held it in 5 quarters. The position peaked at $14K in Q3 2021. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2022.

Cetera Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Cetera Advisors sold 222 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3K.
Cetera Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Cetera Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $14K in Q3 2021.
22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Cetera Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.